Pfizer (NYSE:PFE) reported positive topline Phase 2b results for its once monthly GLP-1 obesity candidate PF-3944. The drug, ...

What Pfizer’s recent performance tells you right now Pfizer (PFE) has drawn fresh attention after a period in which the share ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...

68.4% of Pfizer shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders.

Pfizer (NYSE:PFE) agreed to acquire weight loss drug developer Metsera for US$10b, entering the obesity and GLP-1 market. The company signed a licensing deal with Novavax for access to its Matrix-M ...